
Humanity's Trash Is Turning To Rock
Researchers from the University of Glasgow have found that trash and slag, an industrial waste product produced by the glass and steel industry, is turning into solid rock in as little as 35 years.
In a new study, the researchers have documented for the first time a new "rapid anthropoclastic rock cycle," which mimics natural rock cycles but involves human material over accelerated timescales.
It all started when one of the authors came across an aluminum tab found encased in a strange rock along the coast of Derwent Howe in West Cumbria.
Derwent Howe was home to iron and steel-making foundries during the 19th and 20th centuries, and its coast accumulated an estimated 27 million cubic-meters of furnace slag over the course of its industrial history.
The slag deposits have formed cliffs of waste material that are being eroded by coastal waves and tides forming sedimentary rocks — resembling the natural rock cycle.
A chemical analysis shows that the slag contains calcium, iron, magnesium and manganese. These elements are highly chemically reactive, which is key to causing the accelerated process of rock formation.
When the slag is eroded by the sea, it exposes the material to seawater and air, which interacts with the slag's reactive elements to create natural cements including calcite, goethite, and brucite. These cements are the same materials that bind together natural sedimentary rocks, but the chemical reactions cause the process to happen much faster.
'For a couple of hundred years, we've understood the rock cycle as a natural process that takes thousands to millions of years,' explains corresponding author Dr. Amanda Owen of the University of Glasgow's School of Geographical and Earth Sciences.
As the eroded slag is deposited and cemented, it incorporates trash carried by waves and currents to the coast.
"What's remarkable here is that we've found these human-made materials being incorporated into natural systems and becoming lithified — essentially turning into rock — over the course of decades instead. It challenges our understanding of how a rock is formed, and suggests that the waste material we've produced in creating the modern world is going to have an irreversible impact on our future."
Almost like real fossils, this trash can be used to date the new 'anthropoclastic rock."
"We were able to date this process with remarkable precision," says Dr. John MacDonald, a co-author of the study. 'We found both a King George V coin from 1934 and an aluminum can tab with a design that we realized couldn't have been manufactured before 1989 embedded in the material. This gives us a maximum timeframe of 35 years for this rock formation, well within the course of a single human lifetime."
Plastiglomerates, a sort of rock resulting from marine plastic pollution, were described for the first time in 2014 from a beach on the Big Island of Hawaii. Since then similar deposits were found along the shores of the Portuguese island of Madeira, the island of Giglio in the Tyrrhenian Sea and in Cornwall in southwest Britain. As plastic pollution is nowadays widespread, likely also plastiglomerates will become more common.
'I think it's very likely that this same phenomenon is happening at any similar slag deposit along a relatively exposed coastline with some wave action anywhere in the world,' explains Dr. David Brown, the paper's third author.
The study,"Evidence for a rapid anthropoclastic rock cycle," was published in the journal Geology.
Additional material and interviews provided by the University of Glasgow.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
16 minutes ago
- Medscape
Trends in Antiseizure Drug Use During Pregnancy
TOPLINE: Prenatal exposure to safer antiseizure medications (ASMs) increased and valproate use decreased, but the use of newer medications with uncertain risks surged. METHODOLOGY: Researchers analysed 55,801 ASM-exposed pregnancies (from 2013 to 2021) out of 8,669,502 total pregnancies documented in the French National Mother-Child Register. ASMs were categorised into three safety tiers: those considered the safest (lamotrigine and levetiracetam), those with uncertain risk (pregabalin, gabapentin, clonazepam, oxcarbazepine, and newer ASMs), and those with acknowledged risk (valproic acid, valpromide, carbamazepine, topiramate, phenobarbital, phenytoin, and primidone). The maternal age was 15-49 years; socioeconomic status was assessed via health insurance, and diagnoses were confirmed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes. Maternal and pregnancy characteristics, along with ASM treatment characteristics, were analysed over the study period (2013-2021) and by subperiods (2013-2015, 2016-2018, and 2019-2021). The outcome was the temporal change in prenatal ASM exposure rates across safety categories, analysed on the basis of year, diagnosis, and social indicators. TAKEAWAY: Between 2013 and 2021, prenatal exposures to valproic acid and valpromide declined by 84% and 89%, respectively, but terminations rose (+23% and +28%, respectively), and multiple valproate dispensations and sustained live birth exposures fell drastically (valproic acid: -86% and -91% and valpromide: -93% and -96%, respectively). The use of the safest ASMs (lamotrigine and levetiracetam) rose by +30%. The use of ASMs with uncertain risks rose by +33%, notably pregabalin (+49%), gabapentin (+27%), and newer ASMs (+140%). The use of carbamazepine and topiramate decreased to a lesser extent (-40% and -34%, respectively), with nearly 600 newborns exposed to each of these medications between 2019 and 2021; among women with a low level of resources, exposure to ASMs with uncertain or acknowledged risks was higher (18.5% and 17.9%, respectively) than exposure to the safest ASMs or unexposed (13.8% and 13.5%, respectively). Lamotrigine use linked to mood disorders rose by +51%, correlating with a +35% rise in termination rates. Terminations also rose with ASMs with acknowledged risks. IN PRACTICE: "Additional measures are needed to further reduce perinatal exposure to ASMs with acknowledged or uncertain risks, especially among the most socially deprived populations," the authors wrote. SOURCE: This study, led by Pouneh Shahriari, EPI-PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products, French National Health Insurance), Saint-Denis, France, was published online on July 23, 2025, in Neurology. LIMITATIONS: This study was limited by the reliance on prescription claims to determine exposure to ASMs and the absence of data on clinical indications for treatment. However, prior research using this dataset supports its reliability for assessing prenatal exposure to ASMs. DISCLOSURES: This study did not report any targeted funding. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
16 minutes ago
- Medscape
Patients With IBD and PSC Face Elevated CRC Risk
TOPLINE: Patients with inflammatory bowel disease (IBD), especially those who had been diagnosed before 20 years of age, and with primary sclerosing cholangitis (PSC) had an elevated risk for colorectal cancer (CRC). METHODOLOGY: Researchers conducted a cohort study to analyse the effect of IBD with and without PSC on the risk for CRC. They enrolled patients with IBD diagnosed between January 1969 and December 2014 from the Swedish National Patient Register, including those who underwent colectomy. Patients were classified as those having PSC on the basis of the diagnosis of cholangitis. A total of 85,813 patients with IBD alone and 3066 with IBD and concomitant PSC were included. Each patient with IBD was matched with five control individuals from the general population without IBD (n = 432,037). Information on the diagnosis of CRC and cause of death was obtained using register data. Synchronous cancer was defined as two or more CRCs occurring within or less than 180 days. TAKEAWAY: Patients with IBD and concomitant PSC and those without PSC had an increased risk for CRC (incidence rate [IR], 269 and 95 cases per 100,000 person-years, respectively) compared with matched control individuals (IR, 58 cases per 100,000 person-years; P < .001). Those with unclassified IBD and PSC had the highest risk for CRC (IR ratio [IRR], 7.38; 95% CI, 5.56-9.63). Compared with control individuals, patients diagnosed with IBD before the age of 20 years, with or without PSC, demonstrated a significantly elevated risk for CRC (IRR, 74.97 and 18.75, respectively; P < .001). CRC was more likely to be in the proximal colon among patients with IBD and PSC than among those with IBD without PSC and control individuals, with 37.5% vs 27% and 22.4% of CRC being located in the caecum and ascending colon. Synchronous cancers were found in 4.7% of patients with IBD and PSC and 4.4% of those with IBD without PSC vs 1.9% of control individuals (P < .001). Those with IBD and PSC had the highest mortality (adjusted hazard ratio, 2.56; P < .001). IN PRACTICE: "In PSC+ [IBD with a concomitant PSC diagnosis], primary CRC is more often located in the proximal colon. This must be considered when counselling patients with IBD regarding type of resection for cancer and choice of restorative surgery," the authors of the study wrote. SOURCE: This study was led by Maie Abdalla, MD, PhD, Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. It was published online on July 22, 2025, in Clinical Gastroenterology and Hepatology. LIMITATIONS: The register included only hospital discharge diagnoses before 2001, potentially missing outpatients with milder disease. Variables such as diet, smoking, family history of CRC, colitis severity, tumour stage, and others could not be accounted for. PSC lacks a specific International Classification of Diseases code; therefore, researchers had to combine a cholangitis code with an IBD diagnosis to identify cases. DISCLOSURES: This study was supported by the Medical Research Council of Southeast Sweden and by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement, Sweden. One author reported being an employee of AstraZeneca and having shares in the same. The author also reported receiving prior research funding and honoraria for lectures and consultancy from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Migration fuels second largest annual jump in population in over 75 years
The population of England and Wales is estimated to have jumped by more than 700,000 in the year to June 2024, the second largest annual numerical increase in over 75 years, figures show. Almost all of this rise was due to international migration, with natural change – more births than deaths – accounting for only a small proportion. There were an estimated 61.8 million people in England and Wales in mid-2024, up 706,881 from 61.1 million in mid-2023, according to the Office for National Statistics (ONS). Net international migration – the difference between people moving to the country and leaving – was the 'main driver' of the jump in population and accounted for 98% (690,147) of the increase, the ONS said. The number of people living in England and Wales has risen annually since mid-1982, with migration contributing most to population growth every year since mid-1999. Before then, increases were caused mainly by natural change. The rise of 706,881 in the 12 months to June 2024 is the second biggest year-on-year numerical jump in population since at least 1949, which is the earliest comparable ONS data. It is behind only the rise of 821,210 that took place in the preceding 12 months from mid-2022 to mid-2023. This means the population is estimated to have grown by 1.5 million between June 2022 and June 2024: the largest two-year jump since current records began. Nigel Henretty of the ONS said: 'The population of England and Wales has increased each year since mid-1982. 'The rate of population increase has been higher in recent years, and the rise seen in the year to mid-2024 represents the second largest annual increase in numerical terms in over 75 years. 'Net international migration continues to be the main driver of this growth, continuing the long-term trend seen since the turn of the century.'